EP2441830A3 - Heparan sulfate glycosaminoglycan lyase and uses thereof - Google Patents

Heparan sulfate glycosaminoglycan lyase and uses thereof Download PDF

Info

Publication number
EP2441830A3
EP2441830A3 EP11188293A EP11188293A EP2441830A3 EP 2441830 A3 EP2441830 A3 EP 2441830A3 EP 11188293 A EP11188293 A EP 11188293A EP 11188293 A EP11188293 A EP 11188293A EP 2441830 A3 EP2441830 A3 EP 2441830A3
Authority
EP
European Patent Office
Prior art keywords
heparan sulfate
sulfate glycosaminoglycan
glycosaminoglycan lyase
nucleic acid
acid molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11188293A
Other languages
German (de)
French (fr)
Other versions
EP2441830A2 (en
Inventor
James Myette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of EP2441830A2 publication Critical patent/EP2441830A2/en
Publication of EP2441830A3 publication Critical patent/EP2441830A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0081—Reaction with amino acids, peptides, or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)

Abstract

The invention provides recombinant B. thetaiotaomicron GAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron GAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
EP11188293A 2005-11-03 2006-11-03 Heparan sulfate glycosaminoglycan lyase and uses thereof Withdrawn EP2441830A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/265,908 US7767420B2 (en) 2005-11-03 2005-11-03 Heparan sulfate glycosaminoglycan lyase and uses thereof
EP06836937A EP1942929A4 (en) 2005-11-03 2006-11-03 Heparan sulfate glycosaminoglycan lyase and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP06836937.0 Division 2006-11-03

Publications (2)

Publication Number Publication Date
EP2441830A2 EP2441830A2 (en) 2012-04-18
EP2441830A3 true EP2441830A3 (en) 2012-08-08

Family

ID=37996602

Family Applications (4)

Application Number Title Priority Date Filing Date
EP11188293A Withdrawn EP2441830A3 (en) 2005-11-03 2006-11-03 Heparan sulfate glycosaminoglycan lyase and uses thereof
EP11188288A Withdrawn EP2450441A3 (en) 2005-11-03 2006-11-03 Heparan sulfate glycosaminoglycan lyase and uses thereof
EP11188226A Withdrawn EP2441829A3 (en) 2005-11-03 2006-11-03 Heparan sulfate glycosaminoglycan lyase and uses thereof
EP06836937A Ceased EP1942929A4 (en) 2005-11-03 2006-11-03 Heparan sulfate glycosaminoglycan lyase and uses thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP11188288A Withdrawn EP2450441A3 (en) 2005-11-03 2006-11-03 Heparan sulfate glycosaminoglycan lyase and uses thereof
EP11188226A Withdrawn EP2441829A3 (en) 2005-11-03 2006-11-03 Heparan sulfate glycosaminoglycan lyase and uses thereof
EP06836937A Ceased EP1942929A4 (en) 2005-11-03 2006-11-03 Heparan sulfate glycosaminoglycan lyase and uses thereof

Country Status (7)

Country Link
US (2) US7767420B2 (en)
EP (4) EP2441830A3 (en)
JP (2) JP2009518003A (en)
CN (2) CN101501191B (en)
AU (1) AU2006311794B2 (en)
CA (1) CA2628216A1 (en)
WO (1) WO2007056218A2 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2402753A1 (en) 2002-03-11 2012-01-04 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
AU2003302219B8 (en) * 2002-05-20 2009-03-26 Instituto Di Recherche Chimiche E Biochimiche G. Ronzoni Novel method for sequence determination using NMR
US7691613B2 (en) * 2006-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Glycosaminoglycan lyase IV and uses thereof
US7691612B2 (en) * 2005-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US7767420B2 (en) 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US8986713B2 (en) 2006-05-12 2015-03-24 W. L. Gore & Associates, Inc. Medical device capable of being compacted and expanded having anti-thrombin III binding activity
US20080279909A1 (en) * 2006-05-12 2008-11-13 Cleek Robert L Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization
US8021677B2 (en) 2006-05-12 2011-09-20 Gore Enterprise Holdings, Inc. Immobilized biologically active entities having a high degree of biological activity
US8496953B2 (en) * 2006-05-12 2013-07-30 W. L. Gore & Associates, Inc. Immobilized biologically active entities having a high degree of biological activity following sterilization
US9114194B2 (en) * 2006-05-12 2015-08-25 W. L. Gore & Associates, Inc. Immobilized biologically active entities having high biological activity following mechanical manipulation
US8101733B1 (en) * 2006-06-27 2012-01-24 Momenta Pharmaceuticals, Inc. Methods of evaluating mixtures of polysaccharides
DE102006036326A1 (en) * 2006-08-03 2008-02-07 Charité - Universitätsmedizin Berlin Dendritic polyglycerol sulfates and sulfonates and their use in inflammatory diseases
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
US7790466B1 (en) 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
KR101561860B1 (en) 2007-11-02 2015-10-20 모멘타 파머슈티컬스 인코포레이티드 Non-anticoagulant polysaccharide compositions
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2567079T3 (en) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Polysaccharide compositions that are not anticoagulants
JP5176229B2 (en) * 2008-03-04 2013-04-03 国立大学法人福井大学 Drugs for allergic diseases and markers of therapeutic effects
EP2419736B1 (en) * 2009-04-16 2014-01-29 Momenta Pharmaceuticals, Inc. Methods of assessing activity of a polysaccharide composition
US8591932B2 (en) * 2009-09-17 2013-11-26 W. L. Gore & Associates, Inc. Heparin entities and methods of use
ES2817779T3 (en) * 2010-01-19 2021-04-08 Momenta Pharmaceuticals Inc Evaluation of heparin preparations
US9387256B2 (en) 2010-04-16 2016-07-12 Momenta Pharmaceuticals, Inc. Tissue targeting
AU2011268470B2 (en) 2010-06-17 2017-02-02 Momenta Pharmaceuticals, Inc. Methods and compositions for promoting hair growth
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
EP2683420B1 (en) 2011-03-11 2018-05-23 W. L. Gore & Associates, Inc. Improvements to immobilised biological entities
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
JP2016520613A (en) 2013-05-28 2016-07-14 モメンタ ファーマシューティカルズ インコーポレイテッド Pharmaceutical composition
CN103710411A (en) * 2013-09-16 2014-04-09 北京航空航天大学 Separation method for large fragment heparin oligosaccharide with high smooth muscle cell proliferation inhibition activity
SI3193901T1 (en) 2014-12-23 2018-06-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
EP3395351A1 (en) 2014-12-23 2018-10-31 4D Pharma Research Limited Immune modulation
LT3206700T (en) 2015-06-15 2019-08-26 4D Pharma Research Limited Compositions comprising bacterial strains
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
MX2017016529A (en) 2015-06-15 2018-03-12 4D Pharma Res Ltd Compositions comprising bacterial strains.
KR20180012846A (en) 2015-06-15 2018-02-06 4디 파마 리서치 리미티드 Composition Containing Bacterial Strain
LT3209310T (en) 2015-11-20 2018-04-25 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
SG10201913557TA (en) 2016-03-04 2020-02-27 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
TW201821093A (en) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 Compositions comprising bacterial strains
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
EP3630136B1 (en) 2017-05-22 2021-04-21 4D Pharma Research Limited Compositions comprising bacterial strains
TW201907931A (en) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 Composition comprising a bacterial strain
TW201919670A (en) 2017-06-14 2019-06-01 英商4D製藥研究有限公司 Compositions comprising bacterial strains
CN111032061A (en) 2017-06-14 2020-04-17 4D制药研究有限公司 Compositions comprising bacterial strains
CN109385412A (en) * 2018-09-18 2019-02-26 天津科技大学 A kind of high expression high activity bacteroides thetaiotaomicron Heparinase I fusion protein and its encoding gene and application
CN109706137B (en) * 2019-01-21 2021-02-19 天津科技大学 Mutant for improving heat stability of heparinase I by increasing disulfide bonds and preparation method thereof
CN111471669B (en) * 2019-08-14 2021-01-29 南京汉欣医药科技有限公司 Heparin lyase mutant and recombinant expression method thereof
CN110628845B (en) * 2019-10-18 2021-12-21 福州大学 Extraction and structure analysis of heparan sulfate/heparin sulfate in oviductus ranae
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use
WO2022040090A1 (en) * 2020-08-17 2022-02-24 The Regents Of The University Of California Application of microbial glycosidase as an anti-viral therapeutic, prognostic, and diagnostic
CN112980820A (en) * 2021-01-25 2021-06-18 上海宝维医药技术有限公司 Method for preparing recombinant heparinase I by utilizing SUMO fusion expression system and SUMO _ heparinase I fusion protein prepared by same
CN113862248B (en) * 2021-10-15 2023-10-03 江南大学 Fusion expression of heparin lyase in bacillus subtilis and application thereof
CN116555229A (en) * 2023-05-25 2023-08-08 云南师范大学 N-acetylglucosaminidase mutant, recombinant expression vector, bacterium and application

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE122007000007I2 (en) 1986-04-09 2010-12-30 Genzyme Corp Genetically transformed animals secreting a desired protein in milk
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
JPH0693836B2 (en) 1988-11-25 1994-11-24 新技術事業団 Heparinase-producing microorganism belonging to the genus Bacillus, novel heparinase, and method for producing the same
DK0452484T3 (en) 1989-11-06 1996-10-14 Cell Genesys Inc Production of proteins by homologous recombination
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5714376A (en) 1991-10-23 1998-02-03 Massachusetts Institute Of Technology Heparinase gene from flavobacterium heparinum
KR100206182B1 (en) 1992-08-11 1999-07-01 박주석 A novel bacillus sp and its selecting method
US5389539A (en) 1992-11-30 1995-02-14 Massachusetts Institute Of Technology Purification of heparinase I, II, and III from Flavobacterium heparinum
US5681733A (en) 1994-06-10 1997-10-28 Ibex Technologies Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
DE69633127T2 (en) 1995-09-29 2005-08-04 BioMarin Pharmaceutical, Inc., Novato USE OF HEPARINAS TO REDUCE INFLAMMATORY REACTIONS
CA2235223A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
KR100257168B1 (en) 1997-03-15 2000-05-15 김영식 Bacteroides sp. hj-15
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
JP2003527822A (en) 1998-08-27 2003-09-24 マサチューセッツ インスティテュート オブ テクノロジー Rationally designed heparinases from heparinases I and II
CA2643162C (en) 1999-04-23 2018-01-02 Massachusetts Institute Of Technology Polymer identification, compositional analysis and sequencing, based on property comparison
WO2001039795A2 (en) 1999-12-02 2001-06-07 Ibex Technologies, Inc. Attenuation of fibroblast proliferation
KR20010055115A (en) 1999-12-07 2001-07-04 공재열 Manufacturing method of oligosaccharide using a insoluble polysaccharides
ATE357506T1 (en) 2000-01-21 2007-04-15 Biomarin Pharm Inc FLAVOBACTERIUM HEPARINUM EXPRESSION SYSTEM
CA2402160C (en) 2000-03-08 2012-02-14 Massachusetts Institute Of Technology Heparinase iii and uses thereof
ATE426805T1 (en) 2000-09-12 2009-04-15 Massachusetts Inst Technology METHODS AND PRODUCTS ASSOCIATED WITH LOW MOLECULAR HEPARIN
KR20020046293A (en) 2000-12-12 2002-06-21 김영식 Novel heparinases derived from Bacteroides stercoris HJ-15 which hydrolyze glycosaminoglycan, a preparing method and a use thereof
CN1244702C (en) 2001-12-30 2006-03-08 中国科学院微生物研究所 Method of producing heparin oligosaccharide using heparinase
DE10207708A1 (en) 2002-02-22 2003-09-04 C G Aneziris Preparing ceramic molded articles, useful e.g. as filters or membranes, from mixture of ceramic starting materials and substrate for microorganisms or enzymes
ES2421134T3 (en) 2002-05-03 2013-08-29 Massachusetts Institute Of Technology delta 4,5 Glicuronidase and uses thereof
AU2003302219B8 (en) 2002-05-20 2009-03-26 Instituto Di Recherche Chimiche E Biochimiche G. Ronzoni Novel method for sequence determination using NMR
CN1312183C (en) 2004-05-19 2007-04-25 清华大学 Heparinase I fusion protein and genes encoding same and expression method thereof
CN100344769C (en) 2005-08-04 2007-10-24 清华大学 Production of low-molecular heparin
CN100355893C (en) 2005-08-18 2007-12-19 清华大学 Method of expressing heparinase and its special expression carrier
US7767420B2 (en) 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US7691612B2 (en) 2005-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [online] 1 June 2003 (2003-06-01), "SubName: Full=Heparin lyase I;", XP002539913, retrieved from EBI accession no. UNIPROT:Q89YQ6 Database accession no. Q89YQ6 *
DATABASE UniProt [online] 1 June 2003 (2003-06-01), "SubName: Full=Heparinase III protein, heparitin sulfate lyase;", XP002669130, retrieved from EBI accession no. UNIPROT:Q89YR9 Database accession no. Q89YR9 *
DATABASE UniProt [online] 1 June 2003 (2003-06-01), "SubName: Full=Heparinase III protein;", XP002539914, retrieved from EBI accession no. UNIPROT:Q89YS4 Database accession no. Q89YS4 *
MYETTE JAMES R ET AL: "The heparin/heparan sulfate 2-O-sulfatase from Flavobacterium heparinum. Molecular cloning, recombinant expression, and biochemical characterization.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 4 APR 2003, vol. 278, no. 14, 4 April 2003 (2003-04-04), pages 12157 - 12166, XP002286057, ISSN: 0021-9258 *
RILEY T V ET AL: "HEPARINASE PRODUCTION BY BACTEROIDES-SPP", MICROBIOS LETTERS, vol. 25, no. 99-100, 1984, pages 141 - 148, XP009121026, ISSN: 0307-5494 *
RILEY T V: "Heparinase production by anaerobic bacteria.", JOURNAL OF CLINICAL PATHOLOGY APR 1987, vol. 40, no. 4, April 1987 (1987-04-01), pages 384 - 386, XP002539911, ISSN: 0021-9746 *
XU J ET AL: "A genomic view of the human bacteroides thetaiotaomicron symbiosis", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, WASHINGTON, DC, vol. 299, 1 March 2003 (2003-03-01), pages 2074 - 2076, XP002970724, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
EP2441830A2 (en) 2012-04-18
US20080171375A1 (en) 2008-07-17
EP2450441A2 (en) 2012-05-09
US20070098708A1 (en) 2007-05-03
AU2006311794A1 (en) 2007-05-18
US7767420B2 (en) 2010-08-03
CN101501191A (en) 2009-08-05
CN101501191B (en) 2013-04-17
CN102634555A (en) 2012-08-15
WO2007056218A2 (en) 2007-05-18
EP1942929A4 (en) 2009-09-16
CA2628216A1 (en) 2007-05-18
EP2441829A2 (en) 2012-04-18
EP2441829A3 (en) 2012-08-08
JP2012213397A (en) 2012-11-08
EP1942929A2 (en) 2008-07-16
JP2009518003A (en) 2009-05-07
AU2006311794B2 (en) 2012-09-20
EP2450441A3 (en) 2012-08-08
WO2007056218A3 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
EP2441829A3 (en) Heparan sulfate glycosaminoglycan lyase and uses thereof
HK1205193A1 (en) Recombinant n-glycosylated proteins from procaryotic cells n-
MX2008001865A (en) Albumin fusion proteins.
MX2009002816A (en) Albumin fusion proteins.
WO2008077945A3 (en) Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
WO2008065372A3 (en) Modified erythropoietin polypeptides and uses thereof for treatment
WO2005121331A8 (en) Truncated galnact2 polypeptides and nucleic acids
EP2857515A3 (en) Polypeptides having amylolytic enhancing activity and polynucleotides encoding same
WO2007133835A8 (en) Ras mutation and compositions and methods related thereto
MY156542A (en) Fgf21 mutants and uses thereof
WO2010129600A3 (en) Fgf21 mutants and uses thereof
WO2009149171A3 (en) Fgf21 mutants and uses thereof
WO2010042747A3 (en) Fgf21 mutants and uses thereof
WO2011036445A3 (en) Polypeptides and uses thereof
MXPA02012743A (en) Il-17 molecules and uses thereof.
WO2005123916A3 (en) Glycosylation-disrupted factor vii variants
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
WO2007060213A3 (en) Erythropoietin polypeptides and uses thereof
WO2005065339A3 (en) Cell cycle genes and related methods of using
WO2010046493A3 (en) Gene transfer vectors comprising at least one isolated dna molecule having insulator and or boundary properties and methods to identify the same
EP2392655A3 (en) Coagulation factor VII polypeptides
WO2006076628A3 (en) Compositions comprising promoter sequences and methods of use
WO2005024006A8 (en) Coagulation factor VII polypeptides
WO2008094316A3 (en) Novel branchiostoma derived fluorescent proteins
WO2005079316A3 (en) Nucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha 1h, encoded proteins and methods of use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1942929

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/04 20060101ALI20120703BHEP

Ipc: C12N 9/88 20060101AFI20120703BHEP

Ipc: C12P 19/04 20060101ALI20120703BHEP

Ipc: C07K 1/00 20060101ALI20120703BHEP

Ipc: C12P 19/00 20060101ALI20120703BHEP

Ipc: C12Q 1/34 20060101ALI20120703BHEP

17P Request for examination filed

Effective date: 20130208

17Q First examination report despatched

Effective date: 20130312

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130723